Reuters logo
BRIEF-J&J's Stelara shows positive results in treatment of systemic lupus erythematosus in phase 2 trial
November 6, 2017 / 1:47 PM / 12 days ago

BRIEF-J&J's Stelara shows positive results in treatment of systemic lupus erythematosus in phase 2 trial

Nov 6 (Reuters) - Johnson & Johnson:

* Stelara® (ustekinumab) shows positive results in treatment of systemic lupus erythematosus in phase 2 trial

* ‍Janssen - positive results from randomized, placebo-controlled phase 2 study investigating anti-interleukin (il)-12/23 monoclonal antibody stelara​

* ‍P Janssen Research & Development says study met primary endpoint​

* ‍Janssen says plans to advance stelara into a phase 3 sle development program in 2018​

* ‍Janssen - stelara did not meet statistical significance in other secondary endpoints​

* Janssen - ‍no deaths have been reported in study to date​

* Janssen Research & Development says study met primary endpoint‍ (refiles to remove extraneous character)​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below